HHS Lets Pharmacies Compound BPC-157 and Five Other Peptides but Leaves Research-Use Sellers Out
HHS's October 28, 2026 interim enforcement discretion policy lets 503A pharmacies and physicians compound BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax under ten conditions, without adding them to the bulks list. Research-use-only sellers are left out, and comments close November 13.